Present and future of lung cancer vaccines

Expert Opinion on Emerging Drugs

Volumn 11, Issue 3, 2006, Pages 445-459

  Raez, Luis E ^a,b   Rosenblatt, Joseph D ^a   Podack, Eckhard R ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

B7.1; BEC; GVAX; Immunotherapy; MUC1; Non small cell lung cancer; Small cell lung cancer; Vaccine

Indexed keywords

ALEMTUZUMAB; ALPHA 1,3 FUCOSYLTRANSFERASE; ALVAC; B7 ANTIGEN; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; DCVAX; DENDRITIC CELL VACCINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GV 1001; INTERLEUKIN 2; LUCANIX; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MUCIN 1; NAVELBINE; PACLITAXEL; RITUXIMAB; THYMOSIN; TRASTUZUMAB; UNCLASSIFIED DRUG; WT1 PROTEIN;

BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LYMPHOMA; REVIEW; SKIN MANIFESTATION; TUMOR CELL;

ANIMALS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748645954     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.3.445     Document Type: Review

References (95)

1. WOO EY, YEH H, CHU CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168:4272-4276.
2. DISIS ML, WEST HL, SCHIFFMAN K: Cancer vaccines for the treatment and prevention of non-small cell lung cancer. Clin. Lung Cancer (2000) 1(4):294-301.
3. GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734-738.
4. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. (2002) 62:5267-5272.
5. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. (2002) 2(6):389-400. Review of the role of suppressor T cells.
6. +) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61(12):4766-4772.
7. ONIZUKA S, TAWARA I, SHIMIZU J, SAKAGUCHI S, FUJITA T, NAKAYAMA E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. (1999) 59(13):3128-3133.
8. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. (1999) 163(10):5211-5218.
9. + regulatory T-cells. J. Clin. Oncol. (2004) 22(14S):164s (abstract 2506). One of the first papers to show improvement of the antitumor effect after depletion of T-regs.
10. THUN MJ, HENLEY J, BURNS D et al.: Lung cancer death rates in lifelong nonsmokers. J Natl. Cancer Inst. (2006) 98(10):691-699.
11. MOUNTAIN CF: Revisions in the International System for staging lung cancer. Chest (1997) 111:1710-1717.
12. KRASANA MJ, REED CE, NUGENT WC et al.: Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach. Ann. Thorac Surg. (1999) 68:201-207.
13. SCHILLER JH, HARRINGTON D, BELANI P et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (1999) 346(2):92-98. Randomised Phase III trials that showed equivalent response and toxicity among third-generation chemotherapy agents.
14. FOSELLA F, PEREIRA JR, VON PAWEL J et al.: Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. (2003) 21:3016-3024. One of the largest NSCLC trials that showed superior survival of docetaxel against vinorelbine once they are combined with cisplatin.
15. SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:4285-4291. Another Phase III trial comparing the third-generation chemotherapy agents for NSCLC.
16. SHEPHERD FA, RODRIGUES PJ, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132. First trial with tyrosine kinase inhibitors that showed survival benefit in NSCLC.
17. NON-SMALL CELL LUNG CANCER COOPERATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized clinical trials. BMJ (1995) 311:899. Very important meta-analysis that suggested use of chemotherapy in NSCLC.
18. STEPHENS RJ, FAIRLAMB D, GOWER N et al.: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a (abstract 1161). Large randomised trial that showed the benefit of chemotherapy compared with standard of care.
19. LILENBAUM RC, HERNDON J, LIST M et al.: Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): the cancer and leukemia group B (CALGB) 9730 study. J. Clin. Oncol. (2005) 23(1):190-196. Two third-generation chemotherapy agents are better than one.
20. SEDERHOLM C: Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a Phase III trial of the Swedish Lung Cancer Study Group. Semin. Oncol. (2002) 29(3 Suppl. 9):50-54.
21. GEORGOULIAS V, PALLIS AG, KOUROUSIS et al.: Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized Phase III study. Clin. Lung Cancer (2003) 4(5):288-293.
22. GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet (2001) 357:1478-1484.
23. KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. (2002) 20:3578-3585.
24. SMIT E, VAN MEERBEE, LIANES P et al.: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin. Oncol. (2003) 21:3909-3917.
25. GRIDELLI C, GALLO C, SHEPHERD F et al.: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21:3025-3034.
26. ALBEROLA B, CAMPS C, PROVENCIO M et al.: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. (2003) 21:3207-3213.
27. SCHILLER JH: Platin or no platin? That is the question. J. Clin. Oncol. (2003) 21:3009-3010.
28. SMITH IE, O'BRIEN ME, TALBOT DC et al.: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. (2001) 19:1336-1343.
29. SOCINSKI MA, SCHELL MJ, PETERMAN A et al.: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:1335-1343. Benefit of chemotherapy seen is limited to four cycles.
30. ANDERSEN O, SORENSON S, BERGMAN B et al.: Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomized study. Lung Cancer (2003) 41:S28 (abstract O-87).
31. BERGMAN B, SORENSON S, STEPHENS RJ et al.: Quality of life as related to duration of chemotherapy in advanced non-small cell lung cancer: a randomized study comprising 297 patients. Lung Cancer (2003) 41:S19 (abstract O-57).
32. KRAZOWSKI M, WENCZL M, BRODOWICZ T et al.: Gemcitabine and cisplatin (GC) ± subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). Lung Cancer (2003) 41:S29 (abstract O-88).
33. LIPSON SD, CHRETIEN PB, MAKUCH R, KENADY DE, COHEN MH: Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. Cancer (1979) 43(3):863-870.
34. ISSELL BF, VALDIVIESO M, HERSH EM, RICHMAN S, GUTTERMAN JU, BODEY GP: Combination chemo-immunotherapy for extensive non-oat cell lung cancer. Cancer Treat. Rep. (1978) 62(7):1059-1063.
35. EINHORN LH, BOND WH, HORNBACK N, JOE BT: Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin. Oncol. (1978) 5(3):309-313.
36. YASUMOTO K, MANABE H, YANAGAWA E et al.: Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin. Cancer Res. (1979) 39(8):3262-3267.
37. YAMAMURA Y, SAKATINI M, OGURAT, AZUMA I: Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer (1979) 43(4):1314-1319.
38. HADZIEV S, MANDULOVA P, KAVAKLIEVA-DIMITROVAJ et al.: BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Neoplasma (1982) 29(1):93-110.
39. MAURER LH, PAJAK T, EATON W et al.: Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J. Clin. Oncol. (1985) 3(7):969-976. Study showing no advantage of adjuvant BCG for SCLC.
40. MATTHAY RA, MAHLER DA, BECK GJ et al.: Intratumoral Bacillus Calmette-Guerin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res. (1986) 46(11):5963-5968.
41. GIACCONE G, DEBRUYNE C, FELIP E et al.: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). ASCO Ann. Meet. Proc. (2004) 22(14S):7020. No benefit in survival was found with the use of BEC2/BCG in SCLC after standard chemotherapy and radiation.
42. SCHILLER JH, MORGAN-IHRIG C, LEVITT ML: Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. (1995) 18(1):47-51.
43. JANSEN RL, SLINGERLAND R, GOEY SH, FRANKS CR, BOLHUIS RL, STOTER G: Interleukin-2 and interferon-α in the treatment of patients with advanced non-small-cell lung cancer. J. Immunother. (1992) 12(1):70-73.
44. LISSONI P, TISI E, BARNI S et al.: Biological and clinical results of a neuro-immunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br. J. Cancer (1982) 66(1):155-158.
45. HANIBUCHI M, YANO S, NISHIOKA Y, YANAGAWA H, KAWANO T, SONE S: Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int. J. Cancer (1998) 78(4):480-485.
46. LARA PN JR, LAPTALO L, LONGMATE J et al.: Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and Phase II trial. Clin. Lung Cancer (2004) 5(4):231-236.
47. KERR C: Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol. (2005) 6(5):266.
48. TYAGI P: Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin. Lung Cancer (2005) 6(5):276-278.
49. BELANI CP, RAMALINGAM S: Bevacizumab extends survival for patients with non-squamous non-small-cell lung cancer. Clin. Lung Cancer (2005) 6(5):267-268. Bevacizumab will become a new agent in the first-line therapy of NSCLC.
50. VUILLEZ JP, KRAEBER-BODERE F, MORO D et al.: Radio-immunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a Phase I/II trial. Clin. Cancer Res. (1999) 5(10 Suppl.):3259s-3267s.
51. LIU B, PODACK ER, ALLISON JP, MALEK TR: Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. (1996) 156:1117-1125.
52. GRANT SC, KRIS MG, HOUGHTON AN et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmerte-Guerin. Clin Cancer Res. (1999) 5:1319-1323.
53. GIACCONE G, DEBRUYNE C: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J. Clin. Oncol. (2004) 22(14S):622s (abstract 7020). No benefit in survival was found with the use of BEC2/BCG in SCLC after standard chemotherapy and radiation.
54. SALGIA R, LYNCH T, SKARIN A et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. J. Clin. Oncol. (2004) 21(4):624-630. Vaccination with GM-CSF is promissory and safe in NSCLC patients.
55. NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96(4):326-331.
56. NEMUNAITIS J: GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J. Control. Release (2003) 91(1-2):225-231.
57. SCHILLER J, NEMUNAITIS J, ROSS H et al.: A Phase II randomized study of GM-CSF gene-modified autologous tumor vaccine (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC). Lung Cancer (2005) 49(Suppl. 2):S91. Data from a randomised Phase II study with GM-CSF presented in the World Lung Cancer Congress.
58. PALMER M, PARKER J, MODI S et al.: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small cell lung cancer. Clin. Lung Cancer (2001) 3(1):49-57. BLP25 vaccine is safe in patients with NSCLC.
59. MURRAY N, BUTTS C, MAKSYMIUK A, MARSHALL E, GOSS G, SOULIERES D: L-BLP25 Non-Small Cell Lung Cancer Study Group. A liposomal MUC1 vaccine for treatment of non-small cell lung cancer (NSCLC); updated survival results from patients with stage IIIB disease. Proc. Am. Soc. Clin. Oncol. (2005) 23:7037. Very interesting data showing benefit for patients with stage IIIB NSCLC.
60. HIRSCHOWITZ EA, FOODY T, KRYSCIO R, DICKSON L, STURGILL J, YANNELLI J: Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(14):2808-2815. Dendritic cell vaccines shows a potential role in NSCLC.
61. YANNELLI JR, STURGILL J, FOODY T, HIRSCHOWITZ E: The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer (2005) 47(3):337-350.
62. RAEZ LE, CASSILETH PA, SCHLESSELMAN J et al.: Allogeneic vaccination with a B7.1 (CD80) HLA-A gene modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22(14):2800-2807. First human trial showing safety with this new B7.1 vaccine.
63. HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human cardnoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49(9):504-514.
64. ERTL HC: Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Curr. Opin. Mol. Ther. (2002) 4:601-605.
65. OKA Y, TSUBOI A, TAGUCHI T et al.: Induction of WT1 (Wilm's tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA (2004) 101(38):13885-13890.
66. + T cell response to MAGE-3 protein in lung cancer patients. J. Immunol. (2004) 172:3289-3296.
67. HEGE KM, CARBONE DP: Lung cancer vaccines and gene therapy. Lung Cancer (2003) 41:S103-S113. Important review of the topic of lung cancer vaccines and gene therapy for NSCLC.
68. VANSTEENKISTE J, ZIELINSKI M, DAHABRE J et al.: Multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). ASCO Ann. Meet. Proc. (2006) 24(18S):7019.
69. BRUNSVIG PF, GJERTSEN M, KVALHEIM G et al.: A Phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. J. Clin. Oncol. (2005) 23(16S):185s (abstract 2580).
70. MORRIS JC, VAHANIAN N, JANIK JE et al.: Phase I study of an antitumor vaccination using α-(1,3) galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2005) 23(16S):187s (abstract 2586).
71. GONZALEZ G, CROMBET T, TORRES F et al.: Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. (2003) 14(3):461-466.
72. SALAZAR LG, FIKES J, SOUTHWOOD S et al.: Immunization of cancer patients with Her-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin. Cancer Res. (2003) 9:5559-5565.
73. 2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC. ASCO Ann. Meet. Proc. (2006) 24(18S):7018.
74. YAMAZAKI K, NGUYEN T, PODACK ER: Cutting edge: tumor secreted heat shock-fusion protein elicits CDS cells for rejection. J. Immunol. (1999) 163:5178-5182.
75. ANDERSON KM, SRIVASTAVA PK: Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses. Immunol. Lett. (2000) 74(1):35-39.
76. KNUTSON KL: Technology evaluation: DCVax, Northwest Biotherapeutics. Curr. Opin. Mol. Ther. (2002) 4(4):403-407.
77. GABRILOVICH DI, MIRZA N, CHIAPPORI A et al.: Initial results of a Phase II trial of patients with extensive stage small cell lung cancer (SCLC) immunized with dendritic cells (DC) transduced with wild-type p53. J. Clin. Oncol. (2005) 23(16S):176s (abstract 2543).
78. KRUG LM, RAGUPATHI G, HOOD C et al.: Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. (2004) 10:6094-6100.
79. CELLA M, SALLUSTO F, LANZAVECCHIA A: Origin, maturation and antigen presenting function of dentritic cells. Curr. Opin. Immunol. (1997) 9(1):10-16.
80. CELLA M, ENGERING A, PINET V, PIETERS J, LANZAVECHIA A: Inflammatory stimuli induce accumulation of MHC class II complexes on dentritic cells. Nature (1997) 388(6644):782-787.
81. LEE CT, WU LF, CIERNIK CH, NADAF-RAHROV, GABRILOVICH D, CARBONE DP: Genetic immunotherapy of established tumors with adenovirus-murinegranulocyte- macrophage colony-stimulating factor. Hum. Gene Ther. (1997) 8:187-193.
82. NAGAI E, OGAWA T, KIELIAN A, IKUBO A, SUZUKI T: Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulatin g factor establish antitumor immunity and eliminate pre-existing tumorsin syngenic mice. Cancer Immunol. Immunother. (1998) 47:72-80.
83. DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543.
84. MACHIELS J, REILLY R, EMENS L et al.: Cyclophosphamide, doxorubicin, and paclitaxel enhance the and tumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. (2001) 61:3689-3697.
85. + cytolytic T lymphocytes. J. Exp. Med. (1996) 183:791-800.
86. LIU B, PODACK ER, ALLISON JP, MALEK TR: Generation of primary tumorspecific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. (1999) 156:1117-1125.
87. NABEL GJ, GORDON D, BISHOP DK et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA (1996) 93:15388-15393.
88. YAMAZAKI K, SPRUILL G, RHODERICK J, SPIELMAN J, SAVARAJ N, PODACK ER: Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res. (1999) 59:4642-4650.
89. VELDERS MP, SCHREIBER H, KAST WM: Active immunization against cancer cells: impediments and advances. Semin. Oncol. (1998) 25:697-706.
90. YAMADA A, KAWANO K, KOGA M et al.: Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res. (2003) 63:2829-2835.
91. FONG L, ENGLEMAN EG: Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. (2000) 18:245-273.
92. BOON T, CEROTTINI JC, VAN DEN EYNDE B et al.: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. (1994) 12:337-365.
93. DRUG LM, GRANT SC, MILLER VA et al.: Strategies to erradicate minimal residual disease in small cell lung cancers: high dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors and BEC2 plus BCG vaccination. Semin. Oncol. (1999) 26:55-61.
94. DING L, LALANI EN, REDDISH M et al.: Immunogenecity of synthetic peptides related to the corepeptide sequence encoded by the human MUC1 gene effect of immunization on the growth of murine mamary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. (1993) 36:9-17.
95. WROBLEWSKI JM, BIXBY DL, BOROWSKI C, YANNELLI JR: Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer (2001) 33(2-3):181-194.